Short answer
Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). April 22, 2026 press release and Investor and Analyst Day presentation filed as substantive exhibits.
Definium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- April 22, 2026 press release and Investor and Analyst Day presentation filed as substantive exhibits
- Materials may contain updated clinical, pipeline, financing, or strategic information relevant to Definium’s valuation
- CEO Robert Barrow signed the filing on April 22, 2026
Item EX-99.1 · Exhibit EX-99.1
- Three pivotal DT120 ODT readouts expected within six months, creating major near-term catalysts for DFTX
- MDD Emerge fully enrolled with 149 patients; topline data targeted for late 2Q 2026
- GAD Voyage fully enrolled with 214 patients; topline data targeted for early 3Q 2026
- GAD Panorama target enrollment updated to 200; topline readout delayed to late 3Q 2026
- PTSD expansion adds Phase 3 Haven study targeting approximately 200 patients, with initiation expected in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Definium Therapeutics, Inc. 8-K filings
Get the next DFTX 8-K as it lands
Follow DFTX for push alerts, or ask the research agent what this filing means.